|
Video: What is a Stock Split?
|
|
Tempest Therapeutics is a biopharmaceutical company, focused on developing treatments for endocrine diseases. Co.'s three product candidates are: Livoletide (AZP-531), which is for the treatment Prader-Willi syndrome, a genetic endocrine disease usually characterized by hyperphagia, or insatiable hunger; nevanimibe (ATR-101), which is a potential treatment for patients with congenital adrenal hyperplasia, a monogenic adrenal disease that requires lifelong treatment with exogenous cortisol, often at high doses; and NK3R antagonist (MLE-301), which is a potential treatment of vasomotor symptoms commonly known as hot flashes and night sweats, in menopausal women. According to our TPST split history records, Tempest Therapeutics has had 1 split. | |
|
Tempest Therapeutics (TPST) has 1 split in our TPST split history database. The split for TPST took place on June 28, 2021. This was a 1 for 15 reverse split, meaning for each 15 shares of TPST owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.
When a company such as Tempest Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the TPST split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Tempest Therapeutics shares, starting with a $10,000 purchase of TPST, presented on a split-history-adjusted basis factoring in the complete TPST split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/29/2014 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$124.35 |
|
End price/share: |
$3.54 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-97.15% |
|
Average Annual Total Return: |
-29.95% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$284.50 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
06/28/2021 | 1 for 15 |
|
|